Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9KP9

PfDXR - Mn2+ - NADPH - TAKK443 quaternary complex

This is a non-PDB format compatible entry.
Summary for 9KP9
Entry DOI10.2210/pdb9kp9/pdb
Related8ZXX
Descriptor1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplastic, NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE, MANGANESE (II) ION, ... (5 entities in total)
Functional Keywordsinhibitor, malaria, isomerase
Biological sourcePlasmodium falciparum (malaria parasite P. falciparum)
Total number of polymer chains1
Total formula weight57021.39
Authors
Takada, S.,Sakamoto, Y.,Tanaka, N. (deposition date: 2024-11-22, release date: 2025-05-21)
Primary citationKnak, T.,Takada, S.,Illarionov, B.,Krisilia, V.,Pessanha de Carvalho, L.,Lungerich, B.,Sakamoto, Y.,Hofmann, S.,Bacher, A.,Kalscheuer, R.,Held, J.,Fischer, M.,Tanaka, N.,Kurz, T.
Expanding the Chemical Space of Reverse Fosmidomycin Analogs.
Acs Med.Chem.Lett., 16:136-143, 2025
Cited by
PubMed Abstract: Multidrug-resistant pathogens pose a major threat to human health, necessitating the identification of new drug targets and lead compounds that are not susceptible to cross-resistance. This study demonstrates that novel reverse thia analogs of the phosphonohydroxamic acid antibiotic fosmidomycin inhibit 1-deoxy-d-xylulose 5-phosphate reductoisomerase (DXR), an essential enzyme for , , and that is absent in humans. Some novel analogs with large α-phenyl substituents exhibited strong inhibition across these three DXR orthologues, surpassing the inhibitory activity of fosmidomycin. Despite nanomolar target inhibition, the new DXR inhibitors demonstrated mainly weak or no growth inhibition of the pathogens. Crystallographic studies revealed that compounds and induce an open DXR conformation and that the enzyme selectively binds the -enantiomers. The study underscores the difficulties of achieving potent cellular activity despite strong DXR inhibition and emphasizes the need for novel structural optimization strategies and comprehensive pharmacokinetic studies.
PubMed: 39811140
DOI: 10.1021/acsmedchemlett.4c00501
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.13 Å)
Structure validation

237735

数据于2025-06-18公开中

PDB statisticsPDBj update infoContact PDBjnumon